Semaglutide: tested on its own

288 studies: no other medicine in its arm. Page 3 of 3. Open to participants first (106), then studies with results posted, then the rest; newest registration first within each.

• The Medically Reproducing Bariatric Surgery (MRB) II StudyActive, not recruitingNCT06363747Phase 2/3Report a problem
• Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment StrategyWithdrawnNCT06222437Phase 1Report a problem
• Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes MellitusCompletedNCT06161844Phase 3Report a problem
• A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IIICompletedNCT06097390Phase 1Report a problem
• Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 DiabetesWithdrawnNCT06083675Phase 3Report a problem
• DIALYSIS-TIR StudyActive, not recruitingNCT06042153Phase 4Report a problem
• Semaglutide Therapy for Alcohol Reduction (STAR)Active, not recruitingNCT06015893Phase 2Report a problem
• Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DMActive, not recruitingNCT06005012Phase 2Report a problem
• A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy ParticipantsCompletedNCT05996874Phase 1Report a problem
• Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion TherapiesCompletedNCT05920889Phase 2Report a problem
• Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?CompletedNCT05895643Phase 2Report a problem
• Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)CompletedNCT05892432Phase 2Report a problem
• Semaglutide Therapy for Alcohol Reduction - TulsaCompletedNCT05891587Phase 2Report a problem
• Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)CompletedNCT05890976Phase 3Report a problem
• A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes MellitusCompletedNCT05816057Phase 3Report a problem
• A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightActive, not recruitingNCT05726227Phase 3Report a problem
• Comparison of Body Weight Change Through Different Smeglutide Administration MethodsStatus unknownNCT05616052Phase 4Report a problem
• Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and ObesityWithdrawnNCT05444153Phase 3Report a problem
• Efficacy of Oral Semaglutide in Overweight or ObesityStatus unknownNCT05442450Phase 4Report a problem
• A Study of Cardiovascular Events iN Diabetes PlusActive, not recruitingNCT05441267Phase 4Report a problem
• Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection FractionCompletedNCT05371496Phase 4Report a problem
• Semaglutide in Comorbid Schizophrenia Spectrum Disorder and ObesityActive, not recruitingNCT05333003Not applicableReport a problem
• The POST-ACS StudyStatus unknownNCT05322200Phase 4Report a problem
• Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 DiabetesCompletedNCT05303857Phase 4Report a problem
• Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)Active, not recruitingNCT05254314Phase 2Report a problem
• "Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."Status unknownNCT05249881Early Phase 1Report a problem
• Semaglutide to Reduce Atrial Fibrillation BurdenSuspendedNCT05209165Phase 4Report a problem
• Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes PatientsStatus unknownNCT05147896Not applicableReport a problem
• Latino Semaglutide StudyCompletedNCT05087342Phase 3Report a problem
• Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver DiseaseActive, not recruitingNCT05067621Phase 2Report a problem
• Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)CompletedNCT04979130Phase 4Report a problem
• SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without DiabetesCompletedNCT04889183Phase 3Report a problem
• Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF PatientsWithdrawnNCT04885634Phase 3Report a problem
• The Effect of Semaglutide on Pituitary FunctionCompletedNCT04865744Phase 4Report a problem
• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)Active, not recruitingNCT04822181Phase 3Report a problem
• A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide TabletsCompletedNCT04817644Phase 1Report a problem
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)CompletedNCT04777409Phase 3Report a problem
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)CompletedNCT04777396Phase 3Report a problem
• The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone FractureStatus unknownNCT04702516Phase 1/2Report a problem
• Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19Status unknownNCT04615871Phase 2Report a problem
• Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy PeopleCompletedNCT04524832Phase 1Report a problem
• A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different TimesCompletedNCT04513704Phase 1Report a problem
• Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive DisorderCompletedNCT04466345Phase 2Report a problem
• 16-week Flexible vs. 8-week Semaglutide TitrationStatus unknownNCT04447859Phase 3Report a problem
• Exercise and GLP-1 RA on Insulin SecretionStatus unknownNCT04383197Not applicableReport a problem
• SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 DiabetesWithdrawnNCT04287179Phase 3Report a problem
• The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and ObesityCompletedNCT04263415Phase 4Report a problem
• A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection PensCompletedNCT04238962Phase 1Report a problem
• A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of SemaglutideCompletedNCT04228354Phase 1Report a problem
• A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or ObesityCompletedNCT04187300Phase 1Report a problem
• A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection PensCompletedNCT04152915Phase 1Report a problem
• A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide TabletsCompletedNCT04109508Phase 1Report a problem
• A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide TabletsCompletedNCT04097600Phase 1Report a problem
• A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 DiabetesCompletedNCT04032197Phase 1Report a problem
• A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are ChineseCompletedNCT04016974Phase 1Report a problem
• A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or ObesityTerminatedNCT04012255Phase 1Report a problem
• A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With ObesityCompletedNCT03842202Phase 1Report a problem
• A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesActive, not recruitingNCT03811561Phase 3Report a problem
• GLP1R in Parkinson's DiseaseStatus unknownNCT03659682Phase 2Report a problem
• A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)CompletedNCT03611322Phase 1Report a problem
• A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the LiverCompletedNCT03357380Phase 1Report a problem
• Once Weekly GLP-1 in Persons With Spinal Cord InjuryCompletedNCT03292315Phase 4Report a problem
• A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese SubjectsCompletedNCT03288740Phase 1Report a problem
• Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male SubjectsCompletedNCT03144271Phase 1Report a problem
• Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.CompletedNCT02877355Phase 1Report a problem
• A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT02773381Phase 1Report a problem
• Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once WeeklyCompletedNCT02557620Phase 1Report a problem
• Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of SemaglutideCompletedNCT02231684Phase 1Report a problem
• A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 DiabetesCompletedNCT02212067Phase 1Report a problem
• Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02210871Phase 1Report a problem
• Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy SubjectsCompletedNCT02172313Phase 1Report a problem
• A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian SubjectsCompletedNCT02161588Phase 1Report a problem
• A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 DiabetesCompletedNCT02147431Phase 1Report a problem
• A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian SubjectsCompletedNCT02146079Phase 1Report a problem
• Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With PlaceboCompletedNCT02079870Phase 1Report a problem
• A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy SubjectsCompletedNCT02064348Phase 1Report a problem
• Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male SubjectsCompletedNCT02060266Phase 1Report a problem
• Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic ImpairmentCompletedNCT02016911Phase 1Report a problem
• Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal FunctionCompletedNCT02014259Phase 1Report a problem
• Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male SubjectsCompletedNCT01866748Phase 1Report a problem
• A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing ProcessesCompletedNCT01766245Phase 1Report a problem
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 DiabetesCompletedNCT01686945Phase 1Report a problem
• Pharmacoscintigraphic Investigation of NN9924 in Healthy Male SubjectsCompletedNCT01619345Phase 1Report a problem
• Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male SubjectsCompletedNCT01572753Phase 1Report a problem
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male SubjectsCompletedNCT01272973Phase 1Report a problem
• Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian SubjectsCompletedNCT00851773Phase 1Report a problem
• Effect of Renal Impairment on the Pharmacokinetics of NN9535CompletedNCT00833716Phase 1Report a problem
• A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male SubjectsCompletedNCT00813020Phase 1Report a problem

← Semaglutide